Literature DB >> 3770769

N-Acetyltransferase phenotype of patients with bladder cancer.

A E Karakaya, I Cok, S Sardas, O Gögüs, O S Sardas.   

Abstract

N-Acetyltransferase phenotype has been determined in 109 control subjects and in 23 patients with bladder cancer. Sixty-two per cent of control, and 39% of patients with bladder cancer were phenotypically slow acetylators. This difference was not significant. N-Acetyltransferase phenotype is unlikely to be a major determinant in the development of bladder cancer in the Turkish population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770769     DOI: 10.1177/096032718600500507

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  4 in total

Review 1.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

2.  Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.

Authors:  A K Daly; S Cholerton; M Armstrong; J R Idle
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

Review 3.  N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction.

Authors:  J Green; E Banks; A Berrington; S Darby; H Deo; R Newton
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 4.  Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis.

Authors:  Zongheng Zhu; Jinshan Zhang; Wei Jiang; Xianjue Zhang; Youkong Li; Xiaoming Xu
Journal:  Onco Targets Ther       Date:  2015-12-11       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.